APA (7th ed.) Citation

Alima ALMADIYEVA, Serik IBRAYEV, Assiya TURGAMBAYEVA, Alexandr KOSTYUK, Zayituna KHISMETOVA, & Zhanar AKHMETOVA. (2018). Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Tehran University of Medical Sciences.

Chicago Style (17th ed.) Citation

Alima ALMADIYEVA, Serik IBRAYEV, Assiya TURGAMBAYEVA, Alexandr KOSTYUK, Zayituna KHISMETOVA, and Zhanar AKHMETOVA. Cost-effectiveness of Oral Protease Inhibitors Co-administration Versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Tehran University of Medical Sciences, 2018.

MLA (9th ed.) Citation

Alima ALMADIYEVA, et al. Cost-effectiveness of Oral Protease Inhibitors Co-administration Versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Tehran University of Medical Sciences, 2018.